Skip to main content
Top
Published in: Netherlands Heart Journal 2/2011

Open Access 01-02-2011 | Special Article

The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease

Authors: A. C. J. W. Janssens, A. A. M. Wilde, I. M. van Langen

Published in: Netherlands Heart Journal | Issue 2/2011

Login to get access

Abstract

Expectations are high that increasing knowledge of the genetic basis of cardiovascular disease will eventually lead to personalised medicine—to preventive and therapeutic interventions that are targeted to at-risk individuals on the basis of their genetic profiles. Most cardiovascular diseases are caused by a complex interplay of many genetic variants interacting with many non-genetic risk factors such as diet, exercise, smoking and alcohol consumption. Since several years, genetic susceptibility testing for cardiovascular diseases is being offered via the internet directly to consumers. We discuss five reasons why these tests are not useful, namely: (1) the predictive ability is still limited; (2) the risk models used by the companies are based on assumptions that have not been verified; (3) the predicted risks keep changing when new variants are discovered and added to the test; (4) the tests do not consider non-genetic factors in the prediction of cardiovascular disease risk; and (5) the test results will not change recommendations of preventive interventions. Predictive genetic testing for multifactorial forms of cardiovascular disease clearly lacks benefits for the public. Prevention of disease should therefore remain focused on family history and on non-genetic risk factors as diet and physical activity that can have the strongest impact on disease risk, regardless of genetic susceptibility.
Literature
1.
go back to reference Guttmacher AE, Collins FS. Realizing the promise of genomics in biomedical research. JAMA. 2005;294:1399–402.PubMedCrossRef Guttmacher AE, Collins FS. Realizing the promise of genomics in biomedical research. JAMA. 2005;294:1399–402.PubMedCrossRef
2.
go back to reference Brand A, Brand H, Schulte In den Baumen T. The impact of genetics and genomics on public health. Eur J Hum Genet. 2008;16:5–13.PubMedCrossRef Brand A, Brand H, Schulte In den Baumen T. The impact of genetics and genomics on public health. Eur J Hum Genet. 2008;16:5–13.PubMedCrossRef
3.
go back to reference Hofman N, Tan HL, Alders M, et al. Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment? J Am Coll Cardiol. 2010;55:2570–6.PubMedCrossRef Hofman N, Tan HL, Alders M, et al. Active cascade screening in primary inherited arrhythmia syndromes: does it lead to prophylactic treatment? J Am Coll Cardiol. 2010;55:2570–6.PubMedCrossRef
4.
go back to reference Alders M, Koopmann TT, Christiaans I, et al. Haplotype-sharing analysis implicates chromosome 7q36 harboring DPP6 in familial idiopathic ventricular fibrillation. Am J Hum Genet. 2009;84:468–76.PubMedCrossRef Alders M, Koopmann TT, Christiaans I, et al. Haplotype-sharing analysis implicates chromosome 7q36 harboring DPP6 in familial idiopathic ventricular fibrillation. Am J Hum Genet. 2009;84:468–76.PubMedCrossRef
5.
go back to reference Christiaans I, Birnie E, van Langen IM, et al. The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening. Eur Heart J. 2010;31:842–8.PubMedCrossRef Christiaans I, Birnie E, van Langen IM, et al. The yield of risk stratification for sudden cardiac death in hypertrophic cardiomyopathy myosin-binding protein C gene mutation carriers: focus on predictive screening. Eur Heart J. 2010;31:842–8.PubMedCrossRef
6.
go back to reference Wordsworth S, Leal J, Blair E, et al. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J. 2010;31:926–35.PubMedCrossRef Wordsworth S, Leal J, Blair E, et al. DNA testing for hypertrophic cardiomyopathy: a cost-effectiveness model. Eur Heart J. 2010;31:926–35.PubMedCrossRef
7.
go back to reference Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357:165–8.PubMedCrossRef Umans-Eckenhausen MA, Defesche JC, Sijbrands EJ, et al. Review of first 5 years of screening for familial hypercholesterolaemia in the Netherlands. Lancet. 2001;357:165–8.PubMedCrossRef
8.
go back to reference van Langen IM, Hofman N, Tan HL, et al. Family and population strategies for screening and counselling of inherited cardiac arrhythmias. Ann Med. 2004;36 Suppl 1:116–24.PubMedCrossRef van Langen IM, Hofman N, Tan HL, et al. Family and population strategies for screening and counselling of inherited cardiac arrhythmias. Ann Med. 2004;36 Suppl 1:116–24.PubMedCrossRef
9.
go back to reference Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.PubMed Wilson PW, D’Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837–47.PubMed
10.
go back to reference Paynter NP, Chasman DI, Pare G, et al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010;303:631–7.PubMedCrossRef Paynter NP, Chasman DI, Pare G, et al. Association between a literature-based genetic risk score and cardiovascular events in women. JAMA. 2010;303:631–7.PubMedCrossRef
11.
go back to reference Morrison AC, Bare LA, Chambless LE, et al. Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2007;166:28–35.PubMedCrossRef Morrison AC, Bare LA, Chambless LE, et al. Prediction of coronary heart disease risk using a genetic risk score: the Atherosclerosis Risk in Communities Study. Am J Epidemiol. 2007;166:28–35.PubMedCrossRef
12.
go back to reference Anderson JL, Horne BD, Camp NJ, et al. Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease. Am Heart J. 2010;160:250–6.PubMedCrossRef Anderson JL, Horne BD, Camp NJ, et al. Joint effects of common genetic variants from multiple genes and pathways on the risk of premature coronary artery disease. Am Heart J. 2010;160:250–6.PubMedCrossRef
13.
go back to reference Bare LA, Morrison AC, Rowland CM, et al. Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med. 2007;9:682–9.PubMedCrossRef Bare LA, Morrison AC, Rowland CM, et al. Five common gene variants identify elevated genetic risk for coronary heart disease. Genet Med. 2007;9:682–9.PubMedCrossRef
14.
go back to reference Janssens ACJW, Gwinn M, Bradley LA, et al. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet. 2008;82:593–9.PubMedCrossRef Janssens ACJW, Gwinn M, Bradley LA, et al. A critical appraisal of the scientific basis of commercial genomic profiles used to assess health risks and personalize health interventions. Am J Hum Genet. 2008;82:593–9.PubMedCrossRef
15.
go back to reference Manolio TA. Genome-wide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166–76.PubMedCrossRef Manolio TA. Genome-wide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166–76.PubMedCrossRef
16.
go back to reference van der Net JB, Janssens ACJW, Defesche JC, et al. Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemia. Am J Cardiol. 2009;103:375–80.PubMedCrossRef van der Net JB, Janssens ACJW, Defesche JC, et al. Usefulness of genetic polymorphisms and conventional risk factors to predict coronary heart disease in patients with familial hypercholesterolemia. Am J Cardiol. 2009;103:375–80.PubMedCrossRef
17.
go back to reference Swan M. Multigenic condition risk assessment in direct-to-consumer genomic services. Genet Med. 2010;12:279–88.PubMedCrossRef Swan M. Multigenic condition risk assessment in direct-to-consumer genomic services. Genet Med. 2010;12:279–88.PubMedCrossRef
18.
go back to reference Mihaescu R, van Hoek M, Sijbrands EJ, et al. Evaluation of risk prediction updates from commercial genome-wide scans. Genet Med. 2009;11:588–94.PubMedCrossRef Mihaescu R, van Hoek M, Sijbrands EJ, et al. Evaluation of risk prediction updates from commercial genome-wide scans. Genet Med. 2009;11:588–94.PubMedCrossRef
19.
go back to reference Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358:1240–9.PubMedCrossRef Kathiresan S, Melander O, Anevski D, et al. Polymorphisms associated with cholesterol and risk of cardiovascular events. N Engl J Med. 2008;358:1240–9.PubMedCrossRef
20.
go back to reference Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491–3.PubMedCrossRef Helgadottir A, Thorleifsson G, Manolescu A, et al. A common variant on chromosome 9p21 affects the risk of myocardial infarction. Science. 2007;316:1491–3.PubMedCrossRef
21.
go back to reference Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med. 2009;150:65–72.PubMed Paynter NP, Chasman DI, Buring JE, et al. Cardiovascular disease risk prediction with and without knowledge of genetic variation at chromosome 9p21.3. Ann Intern Med. 2009;150:65–72.PubMed
22.
go back to reference Talmud PJ, Cooper JA, Palmen J, et al. Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem. 2008;54:467–74.PubMedCrossRef Talmud PJ, Cooper JA, Palmen J, et al. Chromosome 9p21.3 coronary heart disease locus genotype and prospective risk of CHD in healthy middle-aged men. Clin Chem. 2008;54:467–74.PubMedCrossRef
23.
go back to reference Howard HC, Borry P. Personal genome testing: do you know what you are buying? Am J Bioeth. 2009;9:11–3.PubMed Howard HC, Borry P. Personal genome testing: do you know what you are buying? Am J Bioeth. 2009;9:11–3.PubMed
24.
go back to reference McGuire AL, Diaz CM, Wang T, et al. Social networkers’ attitudes toward direct-to-consumer personal genome testing. Am J Bioeth. 2009;9:3–10.PubMed McGuire AL, Diaz CM, Wang T, et al. Social networkers’ attitudes toward direct-to-consumer personal genome testing. Am J Bioeth. 2009;9:3–10.PubMed
25.
go back to reference Johansen CT, Lanktree MB, Hegele RA. Translating genomic analyses into improved management of coronary artery disease. Future Cardiol. 2010;6:507–21.PubMedCrossRef Johansen CT, Lanktree MB, Hegele RA. Translating genomic analyses into improved management of coronary artery disease. Future Cardiol. 2010;6:507–21.PubMedCrossRef
26.
go back to reference Janssens ACJW, Van Duijn CM. An epidemiological perspective on the future of direct-to-consumer personal genome testing. Investigative Genetics. 2010;1:10.PubMedCrossRef Janssens ACJW, Van Duijn CM. An epidemiological perspective on the future of direct-to-consumer personal genome testing. Investigative Genetics. 2010;1:10.PubMedCrossRef
Metadata
Title
The sense and nonsense of direct-to-consumer genetic testing for cardiovascular disease
Authors
A. C. J. W. Janssens
A. A. M. Wilde
I. M. van Langen
Publication date
01-02-2011
Publisher
Bohn Stafleu van Loghum
Published in
Netherlands Heart Journal / Issue 2/2011
Print ISSN: 1568-5888
Electronic ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-010-0069-x

Other articles of this Issue 2/2011

Netherlands Heart Journal 2/2011 Go to the issue